Zobrazeno 1 - 10 of 29 pro vyhledávání: '"D Bandari"'
1
Connect India Platform for Connecting Recruiter with Worker
Autor: null Ms. S. D. Bandari, null Pritee Dharme, null Shweta Gharal, null Akshata Godse, null Shivani Salunkhe
Publikováno v: International Journal of Advanced Research in Science, Communication and Technology. :382-387
The present educated age utilizes web for everything right from requesting food to getting recruited. In reality, lackey competitors depend much more on web than some other source like paper or systems administration. In this paper, we attempt to add
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::10882732dd0e5c9359e94f93db3f1457
https://doi.org/10.48175/ijarsct-5692
Zobrazit plný text záznamu
5
Present Status of Common Service Centre in Satara District of Maharashtra State (India)
Autor: Sumalatha D. Bandari, Laxman L. Kumarwad, Rajendra D. Kumbhar
Publikováno v: 2018 8th International Conference on Cloud Computing, Data Science & Engineering (Confluence).
Common people need the different government services in their day to day life. Now days these services are provided by the government through the online channels. The Maharashtra is one of the pioneered states in India which providing the government
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2077d5eb7529fb91a15fd08a9c4288d0
https://doi.org/10.1109/confluence.2018.8442748
Zobrazit plný text záznamu
6
Rebif® Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis
Autor: T. Miller, Brooke Hayward, Barry A Singer, Sibyl Wray, Fernando Dangond, D Bandari, Randy Bennett, D Wynn
Publikováno v: Multiple Sclerosis and Related Disorders. 2:45-56
In clinical studies, treatment with subcutaneous interferon beta-1a (IFNβ-1a) has been shown to reduce relapse rates and slow the progression of physical disability in patients with relapsing forms of multiple sclerosis (MS). A formulation of subcut
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b750c0712f779f1aa60e6e901c1165c
https://doi.org/10.1016/j.msard.2012.07.005
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial
Autor: Olaf Stüve, L. Nguyen, K. Butler, K. Bogardus, G. Remingon, Jesus Lovera, Elliot M. Frohman, Ruth H. Whitham, Y. Courtney, J. Fowler, J. Karman, T. R. Brown, L. Cua, Dennis Bourdette, Vijayshree Yadav, G. Heimburger, J. McAleenan, D. Bandari, Katherine Wild, S. Kilcup, T. Monahan
Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England). 16(6)
Background: Memantine, an NMDA antagonist, is effective for moderate to severe Alzheimer’s disease. Objective: Determine whether memantine improves cognitive performance (CP) among subjects with multiple sclerosis (MS) and cognitive impairment (CI)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8133b5f5451461044ab8fcee77f393f7
https://pubmed.ncbi.nlm.nih.gov/20483885
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje